Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now small index

Vision Degrading Myodesopsia clinical trials

1 of 1 indexed Vision Degrading Myodesopsia trials are currently recruiting.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Vision Degrading Myodesopsia: 1 US clinical trial tracked, 1 recruiting.

Vision Degrading Myodesopsia is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. The most active sponsor is VMR Consulting, running 1 of these trials.

Enrollment posture brief

Registry condition vision-degrading-myodesopsia

OPEN 1 | RECR 100% | LATE 0 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Vision Degrading Myodeso (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Vision Degrading Myodesopsia

Vision Degrading Myodesopsia lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Vision Degrading Myodesopsia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Vision Degrading Myodesopsia is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase Distribution

Phase data not available

Top Sponsors

VMR Consulting 1 trials

Named interventions

Most-linked intervention names on Vision Degrading Myodesopsia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser therapy Device
1 trials

US sites by state

Facility locations filed on Vision Degrading Myodesopsia trials. A trial with sites in several states counts in each.

California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Vision Degrading Myodesopsia page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Vision Degrading Myodesopsia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • VMR Consulting sponsors the most Vision Degrading Myodesopsia trials on record, review their full trial history before evaluating a specific study. See VMR Consulting's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Vision Degrading Myodesopsia condition card totals 1 registered trials; most-linked intervention Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser therapy; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.